
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
MCAD CRISPR Activation Plasmid (h) | sc-402708-ACT | 20 µg | $397.00 |
ACADM encodes human medium-chain acyl-CoA dehydrogenase (MCAD), a mitochondrial flavoprotein that catalyzes the first dehydrogenation step in β-oxidation of medium-chain fatty acyl-CoAs. MCAD activity supports cellular energy homeostasis by enabling efficient fatty acid catabolism during fasting and metabolic stress, linking mitochondrial redox balance to ATP production. Disruption or reduced expression of ACADM is associated with impaired medium-chain fatty acid oxidation and characteristic acylcarnitine accumulation patterns that are widely used in metabolic research. Consequently, ACADM/MCAD is frequently studied in pathways governing mitochondrial function, lipid utilization, and nutrient-responsive transcriptional programs.
MCAD CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous ACADM expression without altering the underlying DNA sequence.
MCAD CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the ACADM locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the ACADM transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous MCAD expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native ACADM locus and enabling the study of MCAD-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of MCAD pathway restoration in tumor cells with silenced or reduced ACADM expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.